Jul 26, 2026·Score 86·Type A — Value-style analysisUsed for established, cash-generative companies — weighs earnings power, valuation against the company's own history and peers, and margin of safety.Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology →$70.31
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses.$68.00($65.00–$71.00)
Target PriceOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology →$85.65
Expected Return
Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Type A - The Cooper Companies, Inc. (COO) 20260726 Stock Analysis
📅 Cooper Companies Key Upcoming Events
August 26, 2026 (estimated)Release of Fiscal Q3 2026 Earnings
Description: Management is expected to report third-quarter results, providing critical visibility into the ongoing recovery trajectory of the Asia-Pacific contact lens market, the impact of recent global tariff pressures on gross margins, and updates on the $50 million annualized savings derived from late 2025 reorganization efforts.
September 2026Update on CooperSurgical Strategic Review and Potential Divestiture
Description: Following the resolution of substantially all claims related to the December 2023 embryo culture media recall, the executive team is actively advancing discussions with multiple financial and strategic parties regarding the outright sale of the CooperSurgical unit. This transaction is expected to fundamentally reshape the corporate structure into a pure-play vision company and reallocate massive capital toward share repurchases.
December 4, 2026 (estimated)Release of Fiscal Q4 2026 and Full-Year Earnings
Description: The definitive report on whether the enterprise successfully navigated macroeconomic friction and achieved its targeted 3.5% to 4.5% organic growth for CooperVision over the fiscal year, alongside final readouts on the $4.285 billion to $4.321 billion total revenue guidance.
🏢 Step 1: Cooper Companies Company Overview & Business Model
Q1-A1. What is Cooper Companies?
Company Name (Ticker): The Cooper Companies, Inc. (COO)
Sector: Healthcare
Exchange: NASDAQ
Founded: 1958
Listing Date: January 21, 1983
Fiscal Year End: October
Headquarters: San Ramon, California
CEO: Albert G. White III
Market Cap: $13.71B
Shares Outstanding: 195.03M
Current Stock Price: $70.31
Annual Dividend Yield: ➖ Not applicable
Ex-dividend Date: ➖ Not applicable
As-of: July 26, 2026 (ET)
Q1-A2. How Does Cooper Companies Make Money?
Core Revenue Generation: The company monetizes the structural, inelastic global demand for vision correction and women’s reproductive health by engineering, manufacturing, and distributing highly specialized, regulated medical devices globally.
Target Audience: The end-users span two distinct and highly captive demographics: retail consumers requiring contact lenses (spherical, toric, multifocal, and myopia-control lenses) for daily vision correction, and healthcare professionals (obstetricians, gynecologists, and specialized fertility clinics) requiring surgical equipment, intrauterine devices, and genomic testing services.
Value Proposition: The enterprise generates immense, predictable recurring revenue through the consumable nature of its primary products. Daily and monthly disposable contact lenses necessitate continuous replenishment by consumers, shielding the top line from traditional discretionary cyclicality. Concurrently, the high-margin specialized clinical equipment, fertility consumables, and genomic services form the irreplaceable operational backbone of global fertility and IVF clinics.
Sales Mechanism: Products are sold globally through a highly entrenched, multi-tiered network. This includes independent eye care practitioners who act as clinical gatekeepers prescribing specific lens brands, corporate retail optical chains, hospital networks, and specialized fertility distributors operating across more than 130 countries.
Q1-A3. Cooper Companies’s Revenue Segments & Core Income Sources
CooperVision (CVI) - 67.2% of Total Revenue:
Contribution: This segment generated $2,609.4 million in fiscal 2024, rising steadily to $723.5 million in Q2 2026 alone (representing 8% year-over-year growth and 4% organic growth), consistently accounting for roughly two-thirds of the overall corporate revenue.
Business Significance: CooperVision operates as the foundational core and primary cash-flow engine of the business, functioning as one of the world’s leading contact lens manufacturers. Growth is structurally driven by the global consumer shift toward premium silicone hydrogel daily disposables (anchored by the MyDay brand ecosystem) and the explosive expansion of pediatric myopia management products like the MiSight lens. The segment requires immense capital expenditure to maintain continuous-flow manufacturing but rewards the enterprise with highly predictable, annuity-like consumer replenishment cycles.
CooperSurgical (CSI) - 32.8% of Total Revenue:
Contribution: The surgical and fertility segment generated $358.0 million in Q2 2026, showcasing strong 8% reported growth and 6% organic growth year-over-year.
Business Significance: CSI operates in the highly specialized, high-margin women’s health and fertility space. It offers the PARAGARD intrauterine device, donor gamete services, and critical in-vitro fertilization (IVF) consumables. While it provides clinical diversification and commands profound pricing power within fertility clinics, management is currently conducting a formal strategic review. The objective is to potentially divest this unit to a financial or strategic buyer, intending to maximize immediate shareholder value and reposition the overarching corporate entity as a streamlined, pure-play vision care oligopolist.
Q1-A4. Who Are Cooper Companies’s Competitors?
Direct Competitors in Vision Care:
Alcon (ALC): A dominant, pure-play force in surgical ophthalmology and vision care, representing the most direct peer in terms of clinical scale, product overlap, and global market reach. Alcon fiercely competes in the premium daily disposable and specialty toric lens markets.
Johnson & Johnson Vision Care: The manufacturer of the globally recognized Acuvue brand, possessing immense marketing leverage, unparalleled consumer brand recognition, and global distribution networks that constantly challenge Cooper’s market share.
Bausch + Lomb: A legacy competitor with a comprehensive portfolio of eye health products, competing heavily on pricing, localized distribution density, and established brand legacy.
Direct Competitors in Medical Devices & Healthcare:
Solventum Corporation (SOLV): A massive spin-off entity with diverse healthcare infrastructure, occasionally overlapping in broader medical device supply chains and specialized hospital procurement contracts.
Industry Position Assessment: Cooper holds a formidable, entrenched position within the global contact lens oligopoly. Its differentiated competitive advantage lies deeply in its unmatched engineering capability to manufacture complex specialty lenses—specifically toric lenses for astigmatism and multifocal lenses for presbyopia—at immense scale and superior clinical yields compared to smaller generic rivals. Furthermore, the company’s pioneering dominance in pediatric myopia control via the FDA-approved MiSight lens establishes a unique, high-growth clinical moat that competitors are currently struggling to replicate with equal clinical efficacy.
Q1-A5. Cooper Companies Key Events: Past 12 Months
September 26, 2023Transferred stock exchange listing from the NYSE to NASDAQ
Description: In a strategic move intended to align the corporate profile with other highly innovative, technology-forward medical device companies, management successfully transferred the listing of common stock to the NASDAQ Global Select Market under the same “COO” ticker, aiming to attract growth-oriented institutional capital.
December 2023Initiated voluntary recall of embryo culture media at CooperSurgical
Description: A severe operational and quality control failure led to a global recall of certain lots of embryo culture media, triggering devastating product liability lawsuits from fertility patients whose procedures failed, which subsequently resulted in a massive structural and psychological overhang on the stock.
February 20, 2024Executed a four-for-one stock split
Description: To increase accessibility for retail investors, optimize equity compensation structures, and improve overall trading liquidity, the company divided each share of common stock into four. This adjusted the pre-split trading price of approximately $376 down proportionally to the $94 range without altering the underlying market capitalization.
December 22, 2025Entered into a definitive agreement with activist investor Browning West
Description: Following institutional pressure regarding suboptimal capital allocation and strategic direction, the company agreed to appoint an independent director, Robert Rosebrough, backed by Browning West to the Board of Directors and the Nominating Committee. This signaled a definitive pivot toward aggressive shareholder value realization and disciplined cost optimization.
June 4, 2026Announced resolution of substantially all CooperSurgical recall litigation claims
Description: Management booked a massive $271.6 million net pre-tax charge (comprising $324.1 million in accrued liabilities offset by $52.5 million in expected insurance recoveries) to officially settle over 95% of the IVF culture media claims. This effectively cleared the toxic legal overhang, allowing the firm to cleanly market the unit for sale.
June 4, 2026Confirmed advanced discussions to sell the CooperSurgical business
Description: Alongside a robust Q2 2026 earnings beat, management formally announced that multiple parties are engaged in active, advanced discussions to acquire the fertility and women’s health unit. This transaction would fundamentally transform the enterprise, isolating the vision business and injecting billions in cash for share repurchases.
Q1-A6. Step 1 Key Takeaways
Step 1 Summary: The company is a highly profitable, dual-engine medical device manufacturer currently undergoing a profound structural metamorphosis. By decisively clearing legacy fertility litigation and actively preparing to divest its surgical unit, the enterprise is positioning itself to unlock massive shareholder value as a streamlined, highly-valued pure-play vision care oligopolist.
Top 3 Red Flags:
1 The significant $271.6 million litigation charge highlights severe historical quality control vulnerabilities within the fertility business, damaging clinical trust and severely depressing short-term GAAP profitability.
2 Notable macroeconomic softness and shifting online purchasing behaviors in the Asia-Pacific region are explicitly dragging on top-line momentum, particularly suppressing consumer upgrades to premium lenses in Japan and China.
3 Persistent gross margin compression originating from elevated global tariffs, logistics inflation, and adverse foreign exchange rate fluctuations affecting repatriated international revenues.
Top 5 Key Financial/Operational Indicators for Next-Level Analysis:
1 The Forward P/E Ratio relative to the anticipated pure-play vision sector mean (specifically benchmarked against Alcon).
2 Free Cash Flow generation trajectories (specifically tracking progress against the $2.2 billion long-term target through 2028).
3 Organic Revenue Growth deceleration metrics within the core CooperVision segment.
5 The absolute sum of outstanding corporate debt relative to the potential cash influx from the CooperSurgical sale.
Top 3 Unconfirmed and Estimated:
1 The exact valuation multiple and final purchase price for the CooperSurgical divestiture (estimated by financial analysts at approximately $4.1 billion).
2 The precise deployment ratio of divestiture proceeds between aggressive share repurchases and total debt extinguishment.
3 The long-term clinical retention rate and market share of the MiSight pediatric lens as direct competitors expedite their own FDA clinical trials.
🏰 Step 2: Cooper Companies’s Economic Moat, Growth & Capital Allocation
Q2-A1. Does Cooper Companies Have a Durable Economic Moat?
Entry barriers: The company benefits from a formidable, extraordinarily wide economic moat rooted in insurmountable regulatory hurdles, specialized mass-manufacturing capabilities, and profound clinical switching costs. Contact lenses are FDA-regulated medical devices (Class II or Class III depending on wear duration), demanding years of rigorous clinical trials and substantial capital to bring novel silicone hydrogel materials to market. Furthermore, the company’s proprietary manufacturing lines require hundreds of millions of dollars in continuous CapEx to achieve the precision yields necessary for competitive unit economics. Once a patient is specifically fitted with a toric or multifocal lens by an optometrist, the hassle, clinical risk, and time required for a refitting create profound brand stickiness, effectively locking out new entrants.
Pricing Power Verification: Operating within a globally entrenched oligopoly alongside Alcon, Johnson & Johnson, and Bausch + Lomb, the company possesses immense, unyielding pricing power. The absolute medical necessity of vision correction ensures that consumer demand remains highly inelastic, even during severe inflationary periods. Management successfully implemented systematic price increases over the last two fiscal years without experiencing material customer churn. This demonstrates an exceptional ability to pass on elevated freight, resin, and raw material costs directly to end consumers and clinical distributors.
Profitability Defense Assessment: While unadjusted Return on Invested Capital (ROIC) screens artificially low (ranging between 2.6% and 4.6%) due to massive historical goodwill accumulation from aggressive acquisitions, the underlying unit economics of the daily disposable lens business defend a structural gross margin near 68%. This highly defensible margin profile guarantees that the underlying cash flow generation remains structurally insulated from generic disruption and pricing wars.
Q2-A2. Is Cooper Companies’s Growth Sustainable?
Industry Structure and Growth Outlook: The company operates in a structurally expanding total addressable market (TAM) that defies traditional economic cyclicality. The global contact lens market is continuously driven by irreversible biological trends: aging populations requiring multifocal solutions for presbyopia, drastically increased digital screen time accelerating the global myopia epidemic, and the steady consumer shift from traditional reusable lenses to premium, healthier daily disposables. The myopia control sub-segment alone represents a multi-billion dollar runway, with the company’s MiSight product demonstrating extraordinary 37% year-over-year growth in recent quarters, securing dominance in a nascent market.
Growth Sustainability: The core growth vector is definitively structural rather than event-based. Vision deterioration is an ongoing biological reality, and the transition to daily silicone hydrogel lenses guarantees compounding, daily recurring revenue. However, three essential downside scenarios could halt or significantly impair growth:
1 A severe, sustained macroeconomic depression in the Asia-Pacific region completely freezing the premiumization trend, trapping middle-class consumers in cheaper legacy hydrogel products.
2 Technological breakthroughs in non-invasive laser refractive surgery or pharmacological interventions (e.g., eye drops) that permanently cure or arrest myopia or presbyopia, eliminating the need for prosthetic lenses.
3 The successful execution of a massive, unified online retail disruption that commoditizes the lens distribution model, stripping clinical pricing power away from optometrists and manufacturers alike, forcing a race to the bottom on price.
Q2-A3. How Does Cooper Companies Allocate Capital & Return Cash?
Reinvestment and Shareholder Returns: Management exercises highly disciplined, ruthless capital allocation aligned with long-term shareholder returns. The company explicitly does not pay a dividend, actively opting to deploy its massive excess liquidity into aggressive share repurchases and strategic debt reduction. Recently, the Board of Directors expanded the share repurchase authorization to a massive $2 billion, having already repurchased $290.1 million of common stock in fiscal 2025 at an average price of $69.30. This continuous contraction of the equity float structurally forces EPS upward.
Strategic Reallocation: The impending sale of the CooperSurgical unit exemplifies brilliant capital efficiency. By recognizing that the fertility business—despite its strong 10% organic growth—distracts from the core vision oligopoly, depresses the overall valuation multiple, and carries outsized litigation risk, management is actively unlocking trapped value. The proceeds from this anticipated $4.1 billion transaction are explicitly earmarked for total debt paydown and accelerated share buybacks, a maneuver that will substantially elevate the theoretical return on equity and simplify the corporate narrative for institutional investors.
Economic Moat (9/10): Entrenched within a global medical oligopoly with insurmountable manufacturing and regulatory barriers, enforcing extreme clinical switching costs and robust pricing power.
Growth Sustainability (6/8): Powered by irreversible structural biological tailwinds in myopia management, though slightly offset by the current macroeconomic drag in the critical Asia-Pacific region.
Capital Allocation (6/7): Executing highly accretive share repurchases combined with brilliant strategic divestiture timing, though the ultimate success remains heavily reliant on executing the M&A transaction at a premium multiple.
Step 2 Summary: The company wields an extraordinarily robust economic moat protected by clinical stickiness, regulatory complexity, and capital-intensive manufacturing. Its willingness to aggressively shrink its equity base while divesting highly profitable but non-core assets proves excellent alignment with long-term shareholder value creation.
💰 Step 3: Is Cooper Companies Profitable? Financial Health Analysis
Q3-A1. Cooper Companies’s Growth & Profitability Trends
Growth and Revenue Indicators: Over the past five years, the company has demonstrated relentless, compounding top-line expansion. Revenue grew steadily from $2.92 billion in FY2021 to $4.09 billion in FY2025, pushing to a trailing twelve-month (TTM) record of $4.23 billion by mid-2026. Free cash flow (FCF) generation has surged proportionally, posting $433.7 million in FY2025 and climbing to $569.5 million TTM. The extreme volatility in statutory GAAP Net Income—which plummeted 43% in the TTM period—is entirely an accounting distortion caused by the one-time $271.6 million litigation settlement for the CooperSurgical embryo media recall. This purely legal charge temporarily masks the exceptionally robust, underlying cash generation of the core vision business.
Profitability Margin and Leverage: The company maintains a fortress-like gross margin hovering securely between 65% and 68%. Through rigorous operational leverage, headcount optimization, and back-office integration executed in late 2025, non-GAAP operating margins have expanded to 27%. This proves that the ‘operating leverage’ effect is powerfully active, with incremental sales growth translating directly into outsized operating profit expansion.
Q3-A2. How Profitable Is Cooper Companies? (Margins & ROIC)
ROIC and Value Creation: The company’s Return on Invested Capital (ROIC) registers at a mathematically low 2.67% to 4.63% over the past three years. When compared to a standard healthcare Weighted Average Cost of Capital (WACC) of roughly 9.0%, this mathematically implies structural value destruction. However, this metric is severely depressed by the massive $3.88 billion in accumulated historical goodwill sitting permanently on the balance sheet, a legacy of decades of aggressive acquisitions (such as Ocular Sciences, Generate Life Sciences, and Cook Medical reproductive health).
Relative Performance: The underlying operational cash generation is vastly superior to what the statutory ROIC suggests. Return on Equity (ROE) sits at roughly 4.59% for FY2025, similarly weighed down by the heavy non-cash amortization of acquired intangibles. However, when isolating the cash flow yield, the company remains highly competitive against smaller med-tech peers, demonstrating that cash generation operates independently of goodwill bloat.
Q3-A3. What Drives Cooper Companies’s Returns? (ROIC Breakdown)
Industry-specific Efficiency Analysis: As a highly specialized medical manufacturing entity operating massive production facilities, the core driver of operational efficiency is facility utilization, proprietary manufacturing yields, and inventory turnover.
Component Breakdown: The company must continuously manufacture millions of precision contact lenses daily to meet global demand. Inventory turnover sits at approximately 1.67x to 1.71x, reflecting the massive logistical and capital requirement of holding tens of thousands of individual SKUs (Stock Keeping Units) covering every permutation of sphere, cylinder, and axis across multiple product lines globally. The high capital intensity of setting up continuous-flow silicone hydrogel lines inherently suppresses asset turnover (0.34x), but the resulting high gross margin (68%) adequately compensates for the heavy capital footprint required to maintain the oligopoly.
Q3-A4. Are Cooper Companies’s Earnings High Quality?
Cash Flow vs. Net Income Discrepancy: The quality of profits is exceptionally high. Operating Cash Flow (OCF) consistently and significantly exceeds GAAP Net Income. The primary drivers of this highly favorable discrepancy are massive non-cash charges, specifically the $199.2 million annual amortization of acquired intangible assets and recent non-cash reorganization charges.
Cash Conversion: The Free Cash Flow to Net Income ratio is currently highly distorted by the recent lump-sum litigation charge. However, historically, the company converts an enormous percentage of its non-GAAP operating profit into actual, deployable cash. This robust conversion engine supports management’s firm, reaffirmed guidance of generating over $2.2 billion in cumulative free cash flow from fiscal 2026 through 2028.
Q3-A5. Is Cooper Companies’s Balance Sheet Healthy? (Debt & Leverage)
Comprehensive Financial Stability: The company maintains a sturdy, highly controllable debt profile optimized for a recurring-revenue business. As of the latest period, total debt stands at $2.46 billion against $138.8 million in cash equivalents, resulting in a net debt position of roughly $2.32 billion.
Leverage Adequacy: The Net Debt to EBITDA ratio sits at a very manageable 2.63x, well within the safety parameters for a highly predictable healthcare business. This leverage acts as a disciplined capital structure rather than a survival threat.
Liquidity and Refinancing: Current operational liquidity is highly sufficient. Furthermore, the potential $4.1 billion cash infusion from the pending CooperSurgical divestiture would completely obliterate the existing debt structure in a single stroke, immediately shifting the company into a massive net-cash position.
Interest Coverage: The company generated $882.6 million in EBITDA against $93.1 million in interest expense in the TTM period, yielding an exceptionally safe interest coverage ratio of approximately 9.4x, proving effortless solvency and immunity to high-interest-rate refinancing walls.
Profitability·Capital Efficiency (6/10): World-class operating margins are heavily obscured by mathematically poor ROIC figures, which are driven entirely by historical acquisition goodwill rather than operational decay.
Cash Flow·Profit Quality (7/8): An unstoppable cash conversion cycle easily funds billion-dollar share buybacks and vastly eclipses statutory net income due to non-cash amortization.
Financial Soundness·Debt Management (5/7): A manageable 2.6x leverage ratio that is entirely secure, with an impending divestiture set to wipe out all debt obligations and supercharge the balance sheet.
Step 3 Summary: Despite statutory metrics like ROIC and Net Income being temporarily bruised by massive goodwill and one-time litigation events, the enterprise is an absolute cash-printing machine. The underlying gross margins and massive free cash flow point to profound, unshakeable financial health.
🔎 Step 4: Cooper Companies Forensic Accounting & Dilution Review
Q4-A1. Does Cooper Companies Have Accounting Red Flags?
Revenue recognition: not found
Evidence: The company recognizes revenue strictly upon the transfer of control of medical devices to global distributors and clinicians in standard accordance with ASC 606. No aggressive channel stuffing, early revenue pulling, or irregular booking patterns have been detected in SEC filings.
Cost capitalization: not found
Evidence: Research and development expenses ($172.8 million TTM) are properly and conservatively expensed as incurred, maintaining clean capitalization procedures and avoiding the artificial inflation of operating margins.
Sharp increase in accounts receivable and inventory: not found
Evidence: Accounts receivable and inventory have grown linearly and in exact proportion to the 5% to 8% overall sales growth rate, indicating steady clinical demand without concerning inventory bloat or collection delays.
Evidence: The company utilizes massive non-GAAP adjustments to communicate underlying performance. In Q2 2026, GAAP EPS of $(0.40) was adjusted upward to a Non-GAAP EPS of $1.21. This enormous bridge was legitimately driven by a strictly non-recurring $271.6 million litigation charge to settle the 2023 embryo culture media recall, alongside $47.7 million in standard intangible amortization. While the adjustment is massive, it is transparently detailed and isolated from core operations.
Q4-A2. Is Cooper Companies Overspending? (Capex & Capital Cycle)
Oversupply Risk Assessment: The company’s capital expenditures (approximately $362.4 million in FY2025) are high but structurally necessary to expand and automate precision silicone hydrogel manufacturing lines. The global contact lens industry is currently operating near capacity limits, and key competitors like Alcon and J&J are similarly constrained by the difficulty of scaling precision optics. There are no signs of reckless overcapacity or an impending capital cycle bust; rather, CapEx is carefully calibrated to meet the surging, medically necessary demand for daily disposables without crashing unit pricing.
Q4-A3. How Sound Is Cooper Companies’s Cash Flow?
Checking the quality of profits: The operating cash flow is exceptionally sound, consistently positive, and vastly superior to reported earnings. The company generated $796.1 million in cash from operations in FY2025, completely dwarfing the $374.9 million in GAAP net income. Fictitious gains or aggressive accruals are nonexistent; the cash generation is entirely derived from the core business of selling physical, high-margin medical devices.
Cash flow stability and dependence: The business does not rely on external financing, capital raises, or debt issuances to fund daily operations. The internal cash generation easily covers all CapEx, interest obligations, and aggressive share repurchases.
Warning Signal Classification: No warning signals are present. Cash flow trends are accelerating upward, insulated entirely from the GAAP noise.
Q4-A4. Is Cooper Companies Diluting Shareholders?
⏪ Confirmed (Past) Dilution: The company is aggressively anti-dilutive. Outstanding basic shares steadily decreased from 199 million in FY2024 to 197 million in the TTM period, effectively retiring equity through its methodical share repurchase campaigns.
⏩ Potential (Future) Dilution & Overhang: The Board of Directors authorized a massive $2 billion share repurchase program in September 2025, of which nearly $1 billion remains available. Future action guarantees aggressive equity contraction rather than dilution, a process that will only violently accelerate if the CooperSurgical unit is sold for cash.
Q4-A5. Data Integrity Check
Period: FY vs TTM/Quarterly Standardization (Standards specified) ➡ (Pass)
Definition: GAAP/Non-GAAP· Unification of FCF definitions, formulas, and adjustments ➡ (Pass)
Number of shares: Unified for basic vs. dilutive, weighted average vs. end-of-period, and SBC inclusion ➡ (Pass)
Unit: Unified currency ($/€), exchange rate, and unit (million/billion) ➡ (Pass)
Single Value Confirmation: Minor discrepancies between StockAnalysis platform data and exact SEC 10-K filings regarding exact share counts (post-split basis) and minor non-operating expenses were reconciled perfectly to the TTM baseline without altering the structural valuation metrics ➡ (Pass)
Accounting anomalies/distortion signals (5/8): While entirely legitimate and transparent, the sheer magnitude of the $271.6 million non-GAAP adjustment for litigation warrants a conservative penalty to reflect the heavy forensic distortion of the income statement.
Cash flow warning signals (6/7): Operating cash flow is immensely powerful, historically stable, and entirely immune to the statutory GAAP volatility caused by legal settlements.
Dilution factors (4/5): The company is an aggressive buyer of its own stock, securing a highly anti-dilutive posture with a massive $1 billion authorization remaining.
Step 4 Summary: Forensic review confirms that despite heavy reliance on non-GAAP metrics to smooth out a one-time litigation disaster, the underlying accounting mechanics are pristine. The company’s cash flow is authentic, and shareholders face absolutely zero structural dilution risk.
👔 Step 5: Cooper Companies Management & Shareholder Alignment
Q5-A1. Can You Trust Cooper Companies’s Management? (Guidance Track Record)
Guidance Hit Rate: CEO Albert White and his executive suite operate with extraordinary precision, having delivered an astonishing 10 consecutive quarters of beating consensus earnings expectations. They systematically under-promise and over-deliver, building immense institutional trust on Wall Street.
Transparency and Consistency Between Words and Actions: Management demonstrated excellent crisis communication regarding the CooperSurgical embryo media recall. Instead of dragging out the legal fight, they rapidly accrued the necessary liabilities, utilized insurance offsets, settled 95% of the claims in a single quarter, and transparently insulated the core business while maintaining strict fiscal guidance.
Q5-A2. What Are Cooper Companies Insiders Doing?
Insider Trading Status and Context Analysis: Over the trailing 12 months, insiders have registered net selling of approximately $6.4 million. Notably, Independent Board Chair Colleen Jay executed a large option exercise, purchasing 7,000 shares at a deep strike price ($39.40) and subsequently managing her exposure. This generalized selling pressure is entirely routine for heavily compensated med-tech executives managing their personal wealth and executing expiring stock-based compensation (SBC) options. It does not reflect a panicked exodus from the C-suite.
Evaluating executive confidence signals: While cluster buying in the open market is absent, management’s overwhelming execution of corporate share buybacks entirely offsets the minor psychological drag of routine insider selling, signaling supreme confidence in the intrinsic value.
Q5-A3. Is Cooper Companies’s Management Aligned With Shareholders?
Voting Rights and Governance Check: The company operates under a standard, democratic single-class voting structure, fully preserving the rights of general shareholders without any entrenched dual-class distortions or protective founder shares.
Performance and Compensation Indicator (KPI) Analysis: Following the integration of activist investor Browning West, executive KPIs are intensely aligned with long-term value creation. The compensation framework heavily prioritizes organic revenue growth, non-GAAP operating margin expansion, and specifically targets the optimization of free cash flow—metrics that strictly punish reckless empire-building.
Incentive alignment assessment: The recent Board reorganization, combined with the formal initiation of the CooperSurgical strategic review, proves that management is willing to radically alter the corporate structure—even sacrificing a third of total revenue—if it serves the ultimate goal of maximizing per-share value for the owners.
Management Trust (5/5): Ten consecutive quarters of flawless earnings beats and textbook crisis management regarding the product recall warrant perfect credibility.
Insider Trends (3/5): Routine options execution and standard net selling create a slight psychological drag, though entirely normal for the sector’s compensation structures.
Governance & Compensation System (4/5): Activist oversight has successfully forced a strategic review, ensuring executive incentives are ruthlessly tied to cash flow generation, margin expansion, and shareholder returns.
Step 5 Summary: Led by a highly competent executive team monitored by active, aggressive shareholders, the governance structure is optimized to unlock massive corporate value. Management’s flawless execution of financial guidance establishes profound market trust.
⛵ Step 6: Cooper Companies Market Flow & Sentiment
Q6-A1. Analyst Consensus vs Cooper Companies Guidance
Guidance gap and direction analysis: Management recently updated its FY2026 non-GAAP EPS guidance to a tight, highly confident range of $4.58 - $4.66, with total revenue tracking between $4.285 billion and $4.321 billion. This aligns perfectly with Wall Street’s consensus EPS estimate of $4.63, indicating that market expectations are flawlessly calibrated with the company’s internal projections.
Tracking recent sentiment changes: Sentiment has been slightly bifurcated in recent weeks. While the Q2 2026 earnings beat pushed the stock significantly higher, analysts at Wells Fargo recently trimmed their price target from $82 to $66, citing concerns over potential EPS dilution depending on the exact execution, tax friction, and structure of the CooperSurgical sale.
Q6-A2. What Is Cooper Companies’s Short Interest?
Analysis focus: Institutional holdings and short selling indicators.
Institutional Trends: The company is overwhelmingly dominated by “smart money,” with institutional investors holding massive positions. Financial titans like Vanguard, BlackRock, and T. Rowe Price anchor the register, alongside highly engaged activist entities like Browning West, ensuring a stable but highly demanding shareholder base.
Short Selling Indicators: Short interest sits at an innocuous, negligible 3.80% of the float. This remarkably low level confirms that hedge funds see absolutely no structural danger in the company, viewing the recent litigation as a resolved, one-off event rather than a systemic collapse vector. Consequently, a mechanical short squeeze is highly unlikely.
Consensus vs Guidance (2/3): Official guidance matches consensus flawlessly, but recent analyst price target cuts introducing M&A execution fears create minor sentiment friction.
Supply/Short Interest (1/2): A negligible 3.8% short interest reflects broad, unshakeable institutional confidence, though it removes the fuel for any violent, mechanical squeeze momentum.
Step 6 Summary: Market sentiment is currently in a holding pattern. Wall Street universally recognizes the tremendous underlying value of the core vision business but remains cautiously positioned until the final mathematics of the CooperSurgical divestiture are officially published.
🚀 Step 7: Cooper Companies Catalysts & Price Triggers
Q7-A1. What Could Move Cooper Companies Stock? (Top 3 Catalysts)
1 Execution of the CooperSurgical Divestiture at Premium Valuation
Timing: Next 3-6 months
Success Conditions: Management successfully secures a private equity or strategic buyer for the CSI unit at the estimated $4.1 billion valuation, utilizing the massive cash proceed to obliterate debt and aggressively retire outstanding shares.
Failure Risk: Credit markets tighten, and bids come in substantially lower than expectations, forcing the company to abandon the sale and retain the slower-margin, litigation-prone unit, instantly crushing market sentiment.
2 Stabilization and Rebound of the Asia-Pacific Vision Market
Timing: Next 6-12 months
Success Conditions: The macroeconomic drag in Japan and China lifts, allowing consumer spending to recover, thereby enabling the core CooperVision segment to reaccelerate top-line organic growth beyond the current 3.5% constraint.
Failure Risk: Prolonged weakness in Asian consumer spending forces further downward revisions on international revenue projections, severely offsetting the tremendous clinical strength in the Americas.
3 Realization of $50 Million Annualized Reorganization Savings
Timing: Next 6-12 months
Success Conditions: The massive back-office integration and AI investments executed in late 2025 successfully drop $50 million directly to the bottom line, permanently expanding the non-GAAP operating margin to 27%+ and proving the operational leverage model.
Failure Risk: Inflationary pressures and global tariffs completely consume the integration savings, flatlining operating leverage and squeezing the gross margin.
Q7-A2. Cooper Companies’s Earnings Revision Trend
Tracking EPS estimate changes: Over the past 90 days, the GAAP EPS estimates for FY2026 have suffered a severe, alarming downward revision—crashing roughly 33% from $3.23 to $2.15. However, this is an entirely artificial statutory revision triggered mechanically by the inclusion of the $271.6 million litigation charge.
Earnings expectations and momentum assessment: Non-GAAP estimates remain rock-solid around the $4.63 mark, confirming that analysts view the core cash-generating engine as fundamentally undamaged and expect the core vision business to continue compounding effortlessly.
Catalyst (6/7): The impending CooperSurgical sale is a generational, transformative catalyst capable of entirely rerating the company’s valuation multiple as a highly prized, pure-play vision oligopolist.
EPS Trend (1/3): While non-GAAP metrics are stable, the severe statutory downward revisions resulting from the litigation settlement mandate a mechanical penalty in this stage.
Step 7 Summary: The company is sitting on a massive powder keg of value creation. If the surgical unit divestiture closes near $4 billion, the resulting financial engineering, debt elimination, and share retirement will act as an explosive upside trigger.
⚖️ Step 8: Is Cooper Companies Fairly Valued? Valuation Analysis
Q8-A1. Cooper Companies’s Key Valuation Multiples (P/E, EV/EBITDA)
PE Ratio: 61.71x (overvalued due to GAAP litigation distortion)
Forward PE: 15.43x (very undervalued)
PEG Ratio: 1.87x (fairly valued)
PS Ratio: 3.37x (undervalued)
PB Ratio: 1.73x (undervalued)
P/TBV Ratio: 5.05x (overvalued)
P/FCF Ratio: 25.03x (fairly valued)
P/OCF Ratio: 14.96x (undervalued)
EV/Sales Ratio: 3.98x (undervalued)
EV/EBITDA Ratio: 19.00x (fairly valued)
EV/EBIT Ratio: 33.57x (overvalued)
EV/FCF Ratio: 29.58x (fairly valued)
Scoring Rationale: When aggressively filtering out the GAAP distortion caused by the Q2 litigation charge, the forward-looking metrics (Forward P/E of 15.4x and Price to Operating Cash Flow of 14.9x) reveal a stock trading at a deep discount relative to its massive free cash flow generation and impenetrable oligopolistic positioning.
📌 (1) Axis Q8-A1 Score:+2
Q8-A2. Cooper Companies vs Peers: Valuation Comparison
Multiple selection based on peer comparison: Forward PER
Calculation of peer-to-peer deviation rate: -39.04%
🧮 Calculation Formula: ((Target company Forward PER 15.43x - Peer Average 25.31x) / Peer Average 25.31x) × 100
Scoring Rationale: Direct vision-care rival Alcon (ALC) commands a Forward P/E exceeding 25x, reflecting the steep premium the market naturally assigns to pure-play ophthalmology assets with recurring revenue. At 15.4x, the company is trading at a massive, nearly 40% structural discount to its most accurate direct peer, penalized artificially by its surgical conglomerate structure.
📌 (2) Axis Q8-A2 Score:+4
Q8-A3. Is Cooper Companies Cheap or Expensive vs Its History?
Comparison Indicators: Forward PER
Scoring Rationale: The company historically commands a Forward P/E multiple oscillating securely between 20x and 25x during normal operational cycles. At the current 15.4x metric, the valuation has collapsed into the bottom 0-20% of its historical 5-year band, punishing the stock for transient litigation fears that are already fully funded, accrued, and settled.
📌 (3) Axis Q8-A3 Score:+4
Q8-A4. What Growth Is Priced Into Cooper Companies? (Reverse DCF)
Implied Growth Rate:4.8%
1 Methodology: Simplified PEG-based inversion
2 Core assumptions: Utilizing the current Forward P/E of 15.43x against a normalized healthcare sector multiple baseline to extract the market’s assumed 5-year EPS growth rate required to justify the current price.
Achievable Growth Rate:12.3%
Basis: Analyst consensus for FY2026 EPS growth (+12.36%) backed by highly predictable recurring contact lens revenue, pediatric myopia expansion, and sustained operating margin expansion.
Scoring Rationale: The market is pricing the stock as if organic growth will permanently stall below 5%. Given the company’s confirmed organic growth trajectory and explosive pediatric myopia runways, beating this artificially low hurdle rate requires virtually no heavy lifting, securing a massive, near-guaranteed margin of safety.
(2) Axis Q8-A2 (Peer-to-peer deviation rate): Very Undervalued (+4)
(3) Axis Q8-A3 (Historical Band Position): Very Undervalued (+4)
(4) Axis Q8-A4 (Justification for Growth): Very Undervalued (+4)
All four foundational valuation axes point identically and strongly toward severe undervaluation, confirming a profound, undeniable disconnect between the stock’s current price and its intrinsic value profile.
📌 (5) Axis Q8-A5 Score:0
Q8-A6. Cooper Companies’s Asset & Stake Valuation
Scoring Rationale: The active strategic review targeting the divestiture of the CooperSurgical unit acts as a massive Sum-of-the-Parts (SOTP) catalyst. With analysts estimating the potential sale price at $4.1 billion, this single asset represents roughly 30% of the entire corporate market cap, revealing substantial hidden value currently trapped by the conglomerate discount.
📌 (6) Axis Q8-A6 Score:+2
Q8-A7. Final Valuation Adjustment
Scoring Rationale: No further exceptional circumstances exist outside the boundaries of the CSI divestiture and litigation normalization already processed systematically in the above axes.
Commentary: The systematic percentile-band methodology and peer comparison strictly confirm that the market is severely mispricing this asset. Paralyzed by the recent GAAP litigation charge and the complexity of the impending surgical divestiture, Wall Street is offering a world-class vision oligopolist at a near 40% discount to its closest peer.
Step 8 Summary: The enterprise is profoundly undervalued across every quantifiable metric. The current price provides an immense margin of safety, assuming the company executes its baseline organic growth without interruption.
💀 Step 9: What Are the Risks of Cooper Companies? Fatal Risks & Pre-Mortem
Q9-A1. What Are the Biggest Risks to Cooper Companies?
1 Failure to Execute the CooperSurgical Divestiture at Favorable Terms
Cause: Tightening credit markets or regulatory pushback restrict private equity buyers from securing the necessary financing to meet the estimated $4.1 billion asking price for the CSI unit.
Impact: Multiple (Permanent loss of the “pure-play” valuation premium).
Mitigation/Monitoring Indicators: Tracking official corporate press releases regarding M&A negotiations and monitoring the debt yields of major healthcare-focused private equity sponsors.
2 Structural Deterioration of the Asia-Pacific Consumer Market
Cause: Prolonged economic stagnation in China and Japan suppresses consumer willingness to upgrade from generic reusable lenses to premium silicone hydrogel daily disposables.
Impact: Financial (Top-line revenue and organic growth stagnation).
Mitigation/Monitoring Indicators: Quarterly tracking of regional revenue breakdowns, specifically isolating the organic growth metric within the CVI Asia-Pacific reporting segment.
3 Escalation of Global Tariffs and Supply Chain Fragmentation
Cause: Intensified geopolitical protectionism results in elevated tariffs and severe disruptions in shipping freight, destroying the cost advantages of globalized manufacturing.
Mitigation/Monitoring Indicators: Monitoring the spread between GAAP and Non-GAAP gross margin, and tracking the Baltic Dry Index for global freight volatility.
Q9-A2. How Sensitive Is Cooper Companies to the Economy?
1 Global Consumer Discretionary Spending (⬇): While vision correction is a medical necessity, the decision to purchase premium daily disposable lenses over cheaper monthly reusables is heavily dependent on middle-class disposable income, directly threatening top-line sales during severe recessions.
2 Foreign Exchange Rate Volatility (⬇): Operating in over 130 countries, a perpetually strong U.S. dollar brutally compresses international revenues upon repatriation, acting as a persistent mathematical drag on reported margins.
Q9-A3. Cooper Companies Pre-Mortem: What Could Go Wrong?
1 The MiSight Monopoly is Shattered: Alcon and J&J successfully navigate FDA trials and launch superior, cheaper pediatric myopia control lenses, sparking a vicious price war that destroys the unit’s highest-growth vertical.
Early Warning Signal: Competitors formally announce FDA approval for novel pediatric myopia contact lens interventions.
2 The Divestiture Collapses and Liability Resurfaces: The CooperSurgical sale falls apart completely, and previously unmodeled long-tail liabilities from the embryo culture media recall emerge, destroying the balance sheet.
Early Warning Signal: Management formally retracts the strategic review without a buyer, followed by an unexpected 8-K filing detailing new class-action fertility lawsuits.
3 Tariffs Erase the Reorganization Savings: Global supply chain chaos and hostile trade policies inflate manufacturing costs faster than the company can implement price hikes, permanently trapping the operating margin below 20%.
Early Warning Signal: Gross margin officially dips below 64% in two consecutive quarters.
Q9-A4. Risk Adjustment Score Calculation
📊 Risk Adjustment Score:-5 pts
Reason for Calculation: The primary risks—Asia-Pacific softness, divestiture execution, and FX/tariff pressures—fall squarely into the controllable, psychological concern bracket (-1 to -10 points). The catastrophic litigation risk has already been quantified and settled via the $271.6 million Q2 charge, neutralizing the threat of sudden bankruptcy or structural ruin.
Step 9 Summary: The downside is heavily insulated. The legacy risks have been flushed through the income statement, leaving only standard macroeconomic and M&A execution hurdles to navigate.
🎯 Step 10: Cooper Companies Final Verdict: Score & Rating
Commentary: The disciplined valuation rule confirms that the stock is highly mispriced. Weighed down by transient legal charges that obscured its massive underlying cash flow, the asset boasts a world-class oligopolistic moat and a transformative, multi-billion-dollar catalyst on the horizon.
Q10-A2. Should You Buy Cooper Companies? (Recommendation)
Recommendation:Buy
Commentary: The immense valuation disconnect—trading at a 40% discount to direct peers while sitting on the precipice of a $4.1 billion corporate restructuring—provides an asymmetric risk-reward profile strongly favoring accumulation.
Q10-A3. Investment Thesis in One Line
The stock represents an immensely undervalued vision oligopolist that will violently rerate higher once the $4.1 billion CooperSurgical divestiture isolates its massive free cash flow engine from legacy litigation noise.
Q10-A4. Cooper Companies’s Price Trend & Key Drivers
Stock Price Trends Over the Past 12 Months:Sideways movement
February 20, 2024Execution of the 4-for-1 stock split
Description: The company structurally altered its share count to lower the nominal entry barrier for retail investors, resulting in a temporary surge of liquidity before the broader market rotation. ➡ Stock Price Reaction
June 4, 2026Massive Q2 Earnings Beat and Divestiture Confirmation
Description: Delivering $1.08 billion in revenue and officially confirming the successful settlement of the CooperSurgical litigation, the market aggressively rewarded the clarity and the formal initiation of the strategic sale process. ➡ Stock Price Surge
Q10-A5. Action Plan
Current Price:$70.31
Buy Zone:$68.00 ($65.00–$71.00)
Commentary: By comprehensively considering the company’s traditional intrinsic value (safety margin) and current market momentum, it calculates a Actionable Buy Zone that minimizes opportunity costs.
(1) Calculation of Fundamental Value: The historical 5-year floor for the Forward P/E multiple sits firmly around 15x. Acquiring shares anywhere below $71 ensures exposure exactly at this fundamental bedrock, heavily insulating against downside risk.
(2) Momentum Premium/Discount Application: With the stock hovering near its 52-week lows and analysts issuing cautious downgrades due to M&A uncertainty, the momentum is suppressed. No premium is granted, allowing entry strictly at intrinsic value.
(3) Conclusion: The calculated $68.00 midpoint perfectly straddles the current trading price, offering immediate entry for investors willing to endure short-term volatility ahead of the divestiture catalyst.
Target Price:$85.65
Expected Return:+21.8% (vs. current price)
📍 Select target stock price calculation criteria:
Forward P/E Multiple — The most accurate proxy for valuing cash-generative, recurring-revenue medical device oligopolies against direct peers.
🧮 Target Price Calculation Formula:
Per share indicator based (Forward PER, P/FCF, etc.): $4.63 × 18.5x = $85.65
Basis for applying the multiple: A multiple of 18.5x is highly conservative. While the direct peer Alcon commands 25x, applying an 18.5x multiple respects the residual execution risk of the CooperSurgical sale while still allowing for a powerful mean-reversion from the current depressed 15.4x level.
Conditions and timing for reaching target price: The target price will likely trigger instantly upon the formal SEC filing announcing the definitive sale of the CooperSurgical unit to a private equity sponsor.
Stop Loss & Investment Thesis Invalidation Criteria:$56.00 ($54.00–$58.00)
Fundamental damage criteria: The thesis shatters if management formally cancels the CooperSurgical sale due to a lack of viable bids, coupled with two consecutive quarters of negative organic growth in the CooperVision Asia-Pacific segment.
Action trigger upon catalyst achievement:
1 Formal announcement of the CooperSurgical sale for $4.0B+
Description: The successful liquidation obliterates debt and funds a massive buyback, permanently boosting EPS and demanding a pure-play multiple rerate. 👉 Increased Holdings (Buy)
2 Confirmation of 27% Non-GAAP Operating Margin for FY2026
Description: Proving that the $50 million reorganization savings successfully insulated the bottom line against global tariffs. 👉 Wait (Hold)
Action triggers when risk realization:
1 Management completely abandons the CooperSurgical divestiture
Description: The conglomerate discount becomes a permanent fixture, and the stock will mechanically bleed downward as the anticipated buyback capital vanishes. 👉 Reduction in Holdings (Sell)
Customized Strategy Guide by Investment Preference:
Defensive Investors: Initiate a half-position at current levels, waiting for the Q3 earnings call to confirm stabilization in the Asia-Pacific market before deploying the remaining capital.
Neutral Investors: Accumulate confidently within the Buy Zone, recognizing the 40% discount to peers provides an exceptional safety margin regardless of exact divestiture timing.
Aggressive Investors: Capitalize on the current M&A uncertainty by heavily overweighting the position, betting that a premium private equity buyout of the surgical unit will spark an immediate and violent upward repricing.
🕵️♂️ Deep Dive Analysis
Q1: Is Cooper Companies’s High Exposure to the Asia-Pacific Market Its Biggest Weakness?
Analysis: The Asia-Pacific (APAC) region currently represents a critical friction point for the overarching growth narrative. During recent quarters, management explicitly noted consumer softness and shifting demand vectors in Japan and China, citing consumers migrating toward more online purchase activity. Consumers in these macroeconomically challenged regions are exhibiting hesitancy to upgrade from legacy hydrogel lenses to premium daily silicone hydrogels, temporarily throttling the aggressive organic growth assumptions built into the CooperVision model. However, this headwind is geographically isolated. The Americas and EMEA regions continue to demonstrate robust, high-single-digit expansion. Furthermore, the myopia epidemic is structurally most severe in the APAC region, mathematically guaranteeing that long-term demand for pediatric interventions like MiSight will eventually override current cyclical constraints.
Judgment:Neutral — While undeniably suppressing top-line momentum in the short term, the biological inevitability of global myopia ensures this weakness is strictly cyclical rather than a permanent structural defect.
Q2: Can Cooper Companies’s 15.4x Forward P/E Be Justified by the Uncertainty of the CooperSurgical Divestiture?
Analysis: The market is brutally penalizing the stock with a 15.4x Forward P/E, a staggering 40% discount to direct pure-play rival Alcon, which trades north of 25x. Wall Street is holding the stock hostage over the mechanics of the CooperSurgical sale. Analysts fear that if the surgical unit (which generates highly profitable fertility revenues) is sold, the resulting “lost earnings” might not be fully offset by the subsequent debt reduction and share repurchases. Wells Fargo specifically lowered their target to $66 based on fears of EPS dilution assuming a $4.1 billion deal price. However, this logic ignores the inherent ‘conglomerate discount’ currently applied to the stock. A streamlined, pure-play vision company instantly commands a higher structural multiple from institutional investors, rendering the current 15.4x valuation a mathematical anomaly driven by temporary uncertainty.
Judgment:Undervalued — The market’s inability to model the exact mechanics of the impending M&A transaction has created an artificial discount. The underlying cash flow from the vision segment alone justifies a multiple closer to 20x.
Q3: How Did the $271.6 Million Litigation Charge Impact Cooper Companies’s Structural Integrity?
Analysis: In December 2023, an operational failure forced the voluntary recall of embryo culture media, inciting severe product liability lawsuits from fertility patients whose IVF cycles failed. By Q2 2026, management executed a masterful, albeit painful, crisis maneuver: they swallowed a massive $271.6 million net pre-tax charge (comprising $324.1 million in accrued liabilities less $52.5 million in expected insurance recoveries) to instantly settle over 95% of the outstanding claims. While this decimated the GAAP Net Income for the quarter—driving EPS down to $(0.40)—it brilliantly quarantined the toxic legal exposure. By flushing the liability entirely through the balance sheet in a single quarter, management cleared the legal overhang that was paralyzing the potential sale of the surgical unit.
Judgment:Positive — Though financially bruising on paper, the swift and ruthless settlement of the litigation preserved the underlying enterprise value and eliminated the existential uncertainty that terrifies institutional capital.
Q4: What Are the Structural Tailwinds Driving CooperVision’s MiSight Pediatric Lenses?
Analysis: The pediatric myopia epidemic is accelerating globally, driven by increased screen time and diminished outdoor activity. CooperVision’s MiSight is the first and only FDA-approved contact lens proven to slow the progression of myopia in children. This product operates entirely outside the traditional competitive parameters of adult vision correction. Because parents are highly insensitive to price when managing their child’s deteriorating eyesight, MiSight possesses immense, inelastic pricing power. Furthermore, fitting a child with MiSight ensures decades of brand loyalty, creating an unparalleled customer lifetime value (LTV) metric. With previous quarters showing 37% year-over-year growth and Q2 2026 continuing robust momentum with a 24% rise in MiSight pediatric myopia control lenses, it stands as the most vital long-term compounding engine within the portfolio.
Judgment:Positive — MiSight represents a generational, monopoly-like asset within a rapidly expanding TAM, insulating the company from generic commoditization.
Q5: How Will the $4.1 Billion CooperSurgical Sale Reprogram the Balance Sheet?
Analysis: The anticipated divestiture of the CooperSurgical unit, estimated by analysts to fetch roughly $4.1 billion, acts as a total financial reset. The company currently carries approximately $2.46 billion in total debt against $138.8 million in cash. Utilizing the sale proceeds to instantaneously wipe out the entire debt load would save roughly $100 million annually in interest expense. The remaining $1.6 billion in excess cash could be deployed immediately into the active $1 billion share repurchase authorization, radically shrinking the equity float. This dual-action financial engineering—eliminating interest drag while contracting the share count—would artificially ignite EPS growth entirely independent of selling a single additional contact lens.
Judgment:Positive — The divestiture is a masterclass in capital allocation, transforming a leveraged, dual-segment medical company into a debt-free, cash-gushing vision oligopolist.
Q6: Can the $50 Million Reorganization Savings Outpace Rising Global Tariffs?
Analysis: In late 2025, management executed severe back-office integrations, leveraging AI and organizational restructuring to unlock $50 million in annualized pre-tax savings, incurring an $89 million one-time charge to achieve it. This was an essential defensive maneuver against a hostile macroeconomic environment fraught with escalating global tariffs and volatile freight costs. Operating across 130 countries requires massive logistical overhead. While tariffs threaten to compress the baseline 68% gross margin, the $50 million in SG&A reductions surgically bypasses the supply chain, dropping directly to the operating margin.
Judgment:Neutral — The reorganization perfectly neutralizes the margin erosion caused by geopolitical trade friction, securing the targeted 27% non-GAAP operating margin, but it does not expand it beyond previous peaks.
Q7: How Has Browning West’s Activism Altered Cooper Companies’s Strategic Trajectory?
Analysis: In December 2025, activist investor Browning West successfully forced a definitive agreement, resulting in the appointment of an independent director, Robert Rosebrough, to the Board and the Nominating Committee. Since this intervention, the corporate posture has shifted violently toward realizing immediate shareholder value. The previously dormant share repurchase program was expanded to $2 billion, and the once-taboo topic of selling the highly profitable (but non-core) CooperSurgical unit was placed front and center. The activist presence guarantees that executive compensation and corporate strategy remain ruthlessly bound to free cash flow generation and margin expansion, preventing management from pursuing empire-building vanity acquisitions.
Judgment:Positive — The activist oversight acts as a powerful catalyst, forcing the unlocking of the conglomerate discount that has plagued the stock for years.
Q8: Does the High Level of Amortization Obscure Cooper Companies’s True Value?
Analysis: A forensic review of the income statement reveals massive non-cash charges, primarily the $199.2 million annual amortization of acquired intangible assets. This amortization stems from decades of legacy acquisitions, most notably the $1.6 billion acquisition of Generate Life Sciences in 2021 and the $875 million acquisition of Cook Medical’s reproductive health business in 2022. Because these are strictly non-cash accounting entries, they artificially crush statutory GAAP Net Income and ROIC, leading unsophisticated algorithms and screeners to flag the company as a low-margin, capital-inefficient enterprise. However, when backing out these phantom charges, the non-GAAP operating margin reveals a highly efficient 27% cash-generating machine.
Judgment:Positive — The massive amortization creates an illusion of poor profitability, shielding the stock from retail momentum while offering astute institutional investors a heavily discounted cash-flow powerhouse.
Q9: Did the February 2024 4-for-1 Stock Split Materially Change the Investment Thesis?
Analysis: On February 20, 2024, the company executed a four-for-one stock split, adjusting the share price from nearly $400 down to the high double digits. While stock splits are mathematically neutral events that do not alter intrinsic value or the fundamental investment thesis, they serve a critical psychological and structural function. By lowering the nominal entry price, the company vastly improved trading liquidity and allowed for more granular employee stock-based compensation (SBC) awards. It broadened the shareholder base, allowing retail participants to accumulate shares more easily, but it did not alter the core valuation multiples or the massive institutional dominance of the float.
Judgment:Neutral — The stock split was a successful mechanical adjustment for liquidity, but it has zero impact on the long-term cash flow capabilities of the enterprise.
Q10: Can Cooper Companies Maintain Its 10-Quarter Earnings Beat Streak?
Analysis: CEO Albert White has orchestrated an incredibly disciplined guidance framework, resulting in 10 consecutive quarters of beating consensus estimates, including the most recent Q2 2026 beat where Non-GAAP EPS hit $1.21 against a $1.10 estimate. This streak is maintained through rigorous sandbagging—deliberately issuing conservative forward guidance that accounts for worst-case macroeconomic scenarios (such as maximum tariff impact and severe FX drag). Because the core business (contact lens replenishment) operates with utility-like predictability, management possesses unparalleled visibility into future cash flows. Unless a completely unforeseen black-swan disruption halts global shipping routes, the mathematical probability of maintaining the beat streak remains exceptionally high.
Judgment:Positive — The combination of a highly predictable consumable medical product and an intentionally conservative guidance philosophy ensures management will continue to systematically outperform market expectations.